Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Nov 1;180(5):1665-73.
doi: 10.1084/jem.180.5.1665.

CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy

Affiliations

CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy

V A Boussiotis et al. J Exp Med. .

Abstract

Induction and maintenance of a state of T cell unresponsiveness to specific alloantigen would have significant implications for human organ transplantation. Using human histocompatibility leukocyte antigen DR7-specific helper T cell clones, we demonstrate that blockade of the B7 family of costimulatory molecules is sufficient to induce alloantigen-specific T cell clonal anergy. Anergized cells do not respond to alloantigen and a variety of costimulatory molecules, including B7-1, B7-2, intercellular adhesion molecule-1 (ICAM-1), and lymphocyte function-associated molecule (LFA)-3. However, after culture in exogenous interleukin (IL)-2 for at least 7 d, anergized cells can respond to alloantigen in the presence of LFA-3. LFA-3 costimulation subsequently restores responsiveness to alloantigen in the presence of previously insufficient costimulatory signals. Expression of CD2R epitope is downregulated on anergic cells and is restored after 7 d of IL-2 culture. The loss of the CD2R is temporally associated with the inability of anergized cells to respond to LFA-3. These results suggest that in addition to blockade of B7 family members, inhibition of CD2 and, potentially, other costimulatory pathways that might reverse anergy will be necessary to maintain prolonged alloantigen-specific tolerance.

PubMed Disclaimer

References

    1. Am J Pathol. 1993 Apr;142(4):1029-40 - PubMed
    1. J Invest Dermatol. 1993 Mar;100(3):275-81 - PubMed
    1. J Exp Med. 1993 Nov 1;178(5):1753-63 - PubMed
    1. J Exp Med. 1993 Nov 1;178(5):1801-6 - PubMed
    1. Science. 1993 Nov 5;262(5135):907-9 - PubMed

Publication types